California Passes Ban on Flavored Tobacco and E-Cigarettes

Nov.11.2022
California Passes Ban on Flavored Tobacco and E-Cigarettes
California bans flavored tobacco and e-cigarettes, becoming the second state to do so.

On November 8th, a bill was passed in California with 58% of voters in favor and 32% against, to maintain the existing ban on flavored tobacco and electronic cigarette products, making it the second state, following Massachusetts, to prohibit the sale of flavored e-cigarettes and traditional cigarettes.


Additionally, it is the fifth state to comprehensively ban flavored e-cigarette products, following Massachusetts (November 2019), Rhode Island (March 2020), New Jersey (April 2020), and New York (May 2020) (click on the blue link to view related documents).


Gavin Newsom, candidate for Governor of California, tweeted that "there are many people coming out to vote, don't miss out - it's time to stand up against those despicable tobacco companies who sell out the future of our children and grandchildren while making a fortune for themselves, it's insane. Please vote YES on Proposition 31 to ensure the flavor ban stays in effect. Saving lives is everyone's responsibility!


Governor Newsom's tweet


An upcoming ban has sparked outrage among interest groups and electronic cigarette users. Tobacco companies such as Reynolds have filed a lawsuit against California (click on the blue font to view related news), and former smokers have commented on Governor Newsom's Twitter in opposition.


Former smokers publish condemnatory comments under Newsom's tweet.


As of October 18, 2022, more areas outside of those states have voted to pass bans on flavored tobacco. These areas include:


Colorado has five.


Georgia state has one.


Illinois has two major cities, one of which is Chicago.


Maine has three major cities, including Portland.


27 cities in Minnesota (including Minneapolis)


Ohio Two


Oregon 1


Pennsylvania has one major city, which is Philadelphia.


And Washington, D.C. as well.


Governments around the world are tightening regulations on electronic cigarettes, and one method of control is to ban flavors. More and more governments may choose this approach. 2FIRSTS will continue to monitor the latest developments regarding electronic cigarette regulations around the world. Stay tuned for updates.


1. This article is only intended for internal discussions and exchanges within the industry and does not promote or recommend any specific brands or products. 2. Smoking is harmful to health. Minors are prohibited from reading this article.


This article is an original piece created by 2FIRSTS Technology Co., Ltd. in Shenzhen. The copyright and license for its use belong to the company, and any unauthorized reproduction, reprinting, or infringement of the company's copyright by any organization or individual is strictly prohibited. The company reserves the right to pursue legal action against any violators.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria has released its full-year 2025 results, reporting full-year net revenues of $23.279 billion, down 3.1% year over year. Domestic cigarette shipment volume fell 10% for the year. on! nicotine pouches reached a 7.7% share of the U.S. oral tobacco category in the fourth quarter. NJOY posted $21 million in net revenues in Q4, while full-year net revenues were negative $13 million (mainly due to returns and related factors).
Jan.30 by 2FIRSTS.ai
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
KDCA youth panel: health indicators worsen with grade level; liquid e-cigarette use tops cigarettes among 11th-grade students
Korea Disease Control and Prevention Agency’s Youth Health Panel Survey (2025) Final Results Report says key adolescent health indicators worsen as students move up grade levels. By 11th grade, lifetime tobacco experience rose to 9.59%. Among 11th-grade girls, current use of liquid e-cigarettes (1.54%) surpassed conventional cigarettes (1.33%) for the first time.
Feb.10 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24